For patients with concurrent DNMT3A mutations, responses to azacytidine have been particularly favorable, suggesting that this mutation may serve as a predictive biomarker for treatment efficacy in VEXAS syndrome [44]. This evidence concerns the gene DNMT3A and VEXAS syndrome.